导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.46% | 1877/4773 |
| 近一周 | -1.97% | 985/5462 |
| 近一月 | -3.32% | 1687/5421 |
| 近一季 | -5.01% | 1748/5209 |
| 近半年 | 0.18% | 1188/4920 |
| 近一年 | 4.81% | 1666/4366 |
| 近两年 | 49.58% | 1474/2954 |
| 近三年 | 31.78% | 977/2253 |
| 成立以来 | 107.08% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.02% 3003/4961 |
11.90% 2272/5312 |
- - |
- - |
| 2025 | 20.25% 2137/4813 |
-0.07% 2049/3635 |
1.47% 2316/4076 |
17.46% 2495/4524 |
0.96% 1633/4813 |
| 2024 | 16.13% 845/3463 |
3.61% 537/2808 |
-0.67% 817/3014 |
15.36% 1740/3129 |
-2.18% 1987/3463 |
| 2023 | -8.94% 1075/2656 |
3.40% 1205/2280 |
-3.29% 765/2385 |
-2.23% 642/2515 |
-6.86% 1947/2655 |
| 2022 | -22.86% 1095/2207 |
-13.65% 806/1919 |
5.60% 863/2016 |
-14.01% 1012/2113 |
-1.61% 1717/2208 |
| 2021 | -1.92% 826/1822 |
-2.82% 709/1255 |
6.62% 734/1330 |
-5.30% 793/1466 |
-0.04% 1187/1822 |
| 2020 | 44.00% 235/1250 |
-7.76% 570/1028 |
18.42% 336/1067 |
15.76% 197/1164 |
13.88% 327/1184 |
| 2019 | 46.55% 133/1092 |
25.13% 480/739 |
0.39% 167/788 |
6.89% 111/850 |
9.15% 251/918 |
| 2018 | -21.60% 216/834 |
- - |
-7.98% 194/631 |
0.55% 150/660 |
-11.98% 389/682 |
| 2017 | 29.36% 66/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝沪深300指数增强A VS. 长安沪深300非周期A(740101) |